These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date Terminated||2005-002857-29||A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease||bad-data|
|Listed as ongoing, but also has a completion date||2007-001421-10||A Randomized, Double-blind, Phase 3 Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma||2009-02-26||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2011-001084-42||A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer||2015-11-04||bad-data|
|Reported results||2012-000558-71||An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women with Breast Cancer||2015-03-17||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-000639-16||A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non- Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)||2014-07-04||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2012-004349-34||A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA||2015-10-21||bad-data|